Eribulin mesylate for the treatment of patients with refractory metastatic breast cancer: Use of a "physician's choice" control arm in a randomized approval trial

Clinical Cancer Research

Volumn 18, Issue 6, 2012, Pages 1496-1505

  Donoghue, Martha ^a   Lemery, Steven J ^a   Yuan, Weishi ^a   He, Kun ^a   Sridhara, Rajeshwari ^a   Shord, Stacy ^a   Zhao, Hong ^a   Marathe, Anshu ^a   Kotch, Lori ^a   Jee, Josephine ^a   Wang, Ying ^a   Zhou, Liang ^a   Adams, William M ^a   Jarral, Vaishali ^a   Pilaro, Anne ^a   Lostritto, Richard ^a   Gootenberg, Joseph E ^a   Keegan, Patricia ^a   Pazdur, Richard ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; ERIBULIN; GEMCITABINE; NAVELBINE; TAXANE DERIVATIVE;

ADULT; AGED; ALOPECIA; ANEMIA; ASTHENIA; BREAST CANCER; CONSTIPATION; DRUG APPROVAL; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURVIVAL TIME; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG APPROVAL; FEMALE; FURANS; HUMANS; KETONES; MULTICENTER STUDIES AS TOPIC; NEOPLASM METASTASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETREATMENT; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84863278868     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2149     Document Type: Review

References (23)

1. Vahdat LT, Pruitt B, Fabian CJ, Rivera RR, Smith DA, Tan-Chiu E, et al. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2009;27:2954-61.
2. Cortes J, Vahdat L, Blum JL, Twelves C, Campone M, Roché H, et al. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol 2010;28:3922-8.
3. Twelves C, Cortes J, Vahdat LT, Wanders J, Akerele C, Kaufman PA. Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clin Breast Cancer 2010;10:160-3.
4. Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, et al. EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) investigators. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 2011;377:914-23.
5. National Cancer Institute [homepage on the Internet]. Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminour R, Waldron W, et al., editors. SEER Cancer Statistics Review, 1975-2007. 2010. [cited 2011 Dec 30] Available from: http://seer.cancer.gov.
6. Centers for Disease Control and Prevention [homepage on the Internet]. U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999-2007 incidence and mortality web-based report. 2010. [cited 2012 Jan 11] Available from: http://www.cdc.gov/uscs.
7. Moreno-Aspitia A, Perez EA. Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends. Clin Ther 2009;31:1619-40.
8. Hirata Y, Uemura D. Halichondrins - antitumor polyether macrolides from a marine sponge. Pure Appl Chem 1986;58:701-10. (Pubitemid 16557441)
9. Lobert S, Vulevic B, Correia JJ. Interaction of vinca alkaloids with tubulin: a comparison of vinblastine, vincristine, and vinorelbine. Biochemistry 1996;35:6806-14. (Pubitemid 26172439)
10. Kingston DG. Tubulin-interactive natural products as anticancer agents. J Nat Prod 2009;72:507-15.
11. Smith JA, Wilson L, Azarenko O, Zhu X, Lewis BM, Littlefield BA, et al. Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry 2010;49:1331-7.
12. Jordan MA, Kamath K, Manna T, Okouneva T, Miller HP, Davis C, et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 2005;4:1086-95. (Pubitemid 41079102)
13. Kotch L, Pilaro A. Pharmacology review application number: 201532. 2010.
14. Synold TW, Morgan RJ, Newman EM, Lenz HJ, Gandara DR, Colevas AD, et al. A phase I pharmacokinetic and target validation study of the novel anti-tubulin agent E7389: a California Cancer Consortium trial. J Clin Oncol 23:16S, 2005 (suppl; abstr 3036).
15. Tan AR, Rubin EH, Walton DC, Shuster DE, Wong YN, Fang F, et al. Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors. Clin Cancer Res 2009;15:4213-9.
16. Goel S, Mita AC, Mita M, Rowinsky EK, Chu QS, Wong N, et al. A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies. Clin Cancer Res 2009;15:4207-12.
17. Ledford H. Complex synthesis yields breast-cancer therapy. Nature 2010;468:608-9.
18. Shord S, Marathe A, Zhao H. Clinical pharmacology and biopharmaceutics reviews NDA 210532. 2010.
19. Halaven (eribulin mesylate) package insert. Andover (MA):Esai; 2011.
20. U.S. Department of Health and Human Services. Guidance for industry. Clinical trial endpoints for the approval of cancer drugs and biologics. Washington, DC: U.S. Dept. of Health and Human Services; 2011.
21. Johnson JR, Williams G, Pazdur R. End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 2003;21:1404-11. (Pubitemid 46606423)
22. U.S. Department of Health and Human Services. Guidance for industry: providing clinical evidence of effectiveness for human drug and biological products. 2011.
23. Cortazar P, Zhang JJ, Sridhara R, Justice RL, Pazdur R. Relationship between OS and PFS in metastatic breast cancer (MBC): review of FDA submission data. J Clin Oncol 29: 2011 (suppl; abstr 1035).